UroGen Pharma (URGN) Revenue (2017 - 2026)
UroGen Pharma's (URGN) quarterly Revenue came in at $51.0 million in Q1 2026, up 151.6% YoY from $20.3 million in Q1 2025, and up 34.68% on a QoQ basis from $37.8 million in Q4 2025.
UroGen Pharma (URGN) Revenue (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Revenue data on file, last reported at $51.0 million in Q1 2026.
- Quarterly Revenue rose 151.6% year-over-year to $51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.5 million (up 52.92% YoY) and the FY2025 annual result came in at $109.8 million, up 21.45% from the prior year.
- Revenue advanced to $51.0 million in Q1 2026, from $37.8 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $51.0 million in Q1 2026 to a low of $13.6 million in Q1 2022.
- A 5-year average of $23.4 million and a median of $21.1 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue rose 3.35% — and 2026, when it jumped 151.6%.
- Tracing URGN's Revenue over 5 years: stood at $18.1 million in 2022, then jumped by 30.06% to $23.5 million in 2023, then gained by 4.4% to $24.6 million in 2024, then soared by 54.03% to $37.8 million in 2025, then surged by 34.68% to $51.0 million in 2026.
- The last three Revenue figures came in at $51.0 million (Q1 2026), $37.8 million (Q4 2025), and $27.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 72.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.46 Mn |
| Mar 31, 2026 | 50.96 Mn |
| Dec 31, 2025 | 37.84 Mn |
| Sep 30, 2025 | 27.48 Mn |
| Jun 30, 2025 | 24.22 Mn |
| Mar 31, 2025 | 20.25 Mn |
| Dec 31, 2024 | 24.57 Mn |
| Sep 30, 2024 | 25.20 Mn |
| Jun 30, 2024 | 21.85 Mn |
| Mar 31, 2024 | 18.78 Mn |
| Dec 31, 2023 | 23.53 Mn |
| Sep 30, 2023 | 20.85 Mn |
| Jun 30, 2023 | 21.14 Mn |
| Mar 31, 2023 | 17.19 Mn |
| Dec 31, 2022 | 18.09 Mn |
| Sep 30, 2022 | 16.10 Mn |
| Jun 30, 2022 | 16.60 Mn |
| Mar 31, 2022 | 13.56 Mn |
| Dec 31, 2021 | 16.17 Mn |
| Sep 30, 2021 | 11.35 Mn |